Tom Goodman

Tom Goodman is a partner in the corporate practice. He has experience advising domestic and international clients on a range of corporate transactions, including public and private mergers and acquisitions (cross border and domestic), venture capital investments, large scale in country and international restructurings, initial public offerings and various other public financing and strategic transactions. He has particular experience in counselling emerging life sciences and technology companies on their formation, recapitalization, corporate governance and general life cycle, including private and public exits.

Tom began his legal career at Covington & Burling where he qualified in September 2010 and practiced for five years prior to joining Cooley's London office.

Notable experience includes advising:

Venture Capital Financings:

• Orchard Therapeutics Limited on its $150 million series C crossover financing
• Orchard Therapeutics Limited on its $110 million series B financing
• Wellington Management Company on its investment in Freeline, a British gene therapy startup, as part of its $80 million Series C financing
• Nightstar Therapeutics plc on its $45 million series C crossover financing
• GIC Private Limited on its investment in Oxford Nanopore Technologies as part of the £100 million raised from global investors, including China Construction Bank International, Hostplus and existing investors
• GIC Private Limited on its $120 million investment in UK-based challenger bank, OakNorth
• Exscientia on its $100 million investment by BlackRock
• AgomAb Therapeutics on its $74 million Series B financing
• Bit Bio on its $41 million Series A financing
• Oribiotech Ltd on its £23 million Series A financing led by Northpond Ventures in a syndicate including Octopus Ventures, Delin Ventures and Amadeus
• Perspectum Diagnostics Ltd on its US$14 million Series B round with BlueCross, BlueShield Venture Partners III and Puhua
• Hummingbird Bioscience on its $25 million extended Series B financing
• DalCor Pharma on the US and UK elements of DalCor UK’ s $50 million series A financing led by Sanderling Ventures and $100 million series B financing round led by Dubai-based investment group Trussbridge Advisory
• Azeria Therapeutics Limited on its £4 million series A financing led by Sixth Element Capital
• MacrophOx Limited on its spin-out from Oxford University and related financing by Oxford Sciences Innovation plc
• Heptares Therapeutics Limited in relation to the spin out of G protein receptor technologies for neurological diseases to Orezia Limited and Inexia Limited and combined €40 million financing led by Medicxi Ventures
• IGEM Therapeutics Limited on its £3 million extension to its series A financing involving Alsa Holdings and UCL Technology Fund
• Delta-v Capital on its investment into Six Degrees, a UK-based provider of collaborative digital solutions
• Storm Therapeutics on its £14 million series A extension with investor syndicate led by Seroba 
• Azeria Therapeutics on its £1.5 million series A extension with CPF Pioneer Fund 
• NeoMed Innovation, IP Group and other investors on its £6.8 million series A extension into Oxular Limited 

Holding Company Restructuring & Capital Markets:

• Autolus Therapeutics, a UK-based clinical-stage biopharmaceutical company, on its $172.5 million IPO on Nasdaq of ordinary shares in the form of American Depositary Shares
• Entasis Therapeutics on its $75 million IPO on Nasdaq
• Nightstar Therapeutics Limited, a UK and Lexington, Massachusetts-based gene therapy company, on its $86 million IPO of ordinary shares in the form of American Depositary Shares
• Nucana plc on its admission to Nasdaq by way of IPO (counsel to underwriters)

M&A and Licensing / Collaborations:

• Flyt Limited on its £22 million sale to strategic investor Just East 
• F-star Delta Ltd. on its €1 billion collaboration with Merck KGaA, including the grant of an option to purchase F-star Delta Ltd.
• F-star Gamma Ltd. on its $1 billion collaboration with Denali Therapeutics, Inc. and subsequent sale for up to $400 million
• Pizza Hut Restaurants UK and its senior leadership team on the management buyout of the business from Rutland Partners
• Qualcomm, Inc. on its $2.5 billion recommended cash offer for CSR plc
• Indivior plc, formerly RB Pharmaceuticals, on its demerger from Reckitt Benckiser and £1 billion listing on the London Main Market
• Heptares Therapeutics Limited on its sale to Sosei Group for up to $400 million
• Microsoft Corporation in connection with its acquisition of the mobile device business of Nokia.
• Local World and its shareholders on the sale of its remaining shares to Trinity Mirror, which will create the UK's largest regional news publisher, valuing Local World at £220 million on a debt-free cash-free basis
• Zenith Hygiene Group plc on its £78 million acquisition by Diversey 
• Journey Group plc on the £24 million recommended cash offer by Jaguar Holdings Limited, which is owned by Harwood Capital Management, for its entire issued and to be issued share capital